Tissue protein turnover in animals treated with the mixed beta-agonist metaproterenol: influence of dose, route and pattern of administration
- PMID: 7508755
- DOI: 10.1016/0300-9084(93)90043-r
Tissue protein turnover in animals treated with the mixed beta-agonist metaproterenol: influence of dose, route and pattern of administration
Abstract
beta-Adrenergic agonists have been shown to increase protein deposition as a result of changes in the balance between protein synthesis and degradation rates. The aim of this study is to investigate the effect of the treatment with the non-selective beta-adrenergic agonist, metaproterenol, on protein metabolism in rats as well as the influence of the route and pattern of administration. A short- and long-term experimental trial were carried out. After the short-term treatment with the beta-agonist (1 mg/kg), neither protein nor nucleic acids were affected in liver or gastrocnemious muscle, while cathepsin A activity, an index of protein degradation, significantly increased in muscle. However, cathepsin A activity was reduced in muscle by the oral administration during 21 days of metaproterenol (2 ppm/day), but not by the subcutaneous injections (0.1 mg/kg/day). On the other hand, RNA/DNA, an index of protein synthesis capacity, and protein/DNA, an indicator of cell size, significantly diminished in muscle after the subcutaneous long-term treatment but did not change in the liver of treated rats. Our study has demonstrated a different outcome of a mixed beta-adrenergic agonist on protein metabolism depending on the duration of the treatment and the route of administration.
Similar articles
-
The influence of oral and subcutaneous administration of a mixed beta-adrenergic agonist on tissue and cell growth.Growth Dev Aging. 1992 Fall;56(3):141-8. Growth Dev Aging. 1992. PMID: 1385342
-
Free intracellular and protein bound amino acids in tissues as affected by a mixed beta-adrenergic agonist.Experientia. 1993 Apr 15;49(4):308-12. doi: 10.1007/BF01923408. Experientia. 1993. PMID: 8477834
-
Repartitioning effect of a mixed beta-agonist on body composition.Rev Esp Fisiol. 1990 Jun;46(2):191-6. Rev Esp Fisiol. 1990. PMID: 1980376
-
Beta-adrenergic agonists and hypertrophy of skeletal muscles.Life Sci. 1992;50(6):397-407. doi: 10.1016/0024-3205(92)90374-x. Life Sci. 1992. PMID: 1346465 Review.
-
The extent and nature of protein degradation in the tissues during development.Reprod Nutr Dev (1980). 1981;21(2):265-77. doi: 10.1051/rnd:19810210. Reprod Nutr Dev (1980). 1981. PMID: 6760290 Review.
Cited by
-
CL316,243, a selective β3-adrenoceptor agonist, activates protein translation through mTOR/p70S6K signaling pathway in rat skeletal muscle cells.Pflugers Arch. 2013 Apr;465(4):509-16. doi: 10.1007/s00424-012-1213-9. Epub 2013 Jan 19. Pflugers Arch. 2013. PMID: 23334408
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources